June 18, 2021
Business News

CytRx Comments on Quarterly Results and Year-to-Date Progress


LOS ANGELES–()–CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the first quarter ended March 31, 2021. In addition, CytRx highlighted developments pertaining to its agreements with Orphazyme A/S (NASDAQ:ORPH) (“Orphazyme”) and ImmunityBio, Inc. (NASDAQ:IBRX) (“ImmunityBio”) as well as Centurion Biopharma. The Company’s 10-Q was filed on May 13, 2021.

Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, stated:

“CytRx continues to execute on its strategic plan to cut costs, maintain a stable capital…



Click here to view the original article.

Related Posts

You might also like ...

The Alpha Blue Ocean Family Office is pleased to announce the appointment of Rajae Elantari as Head of PR & Marketing
AON Splash Image
Arkema annonce le lancement d’une nouvelle gamme innovante de grades PVDF d’origine renouvelable pour les batteries lithium-ion
Le Family Office Alpha Blue Ocean annonce la nomination de Rajae Elantari au poste de Responsable Marketing et Relations Exterieurs